BIVI earnings: next report 2026-09-02, real EPS beat/miss history, analyst consensus Buy, P/E -0.91. Updated 2026-07-23.
BioVie (BIVI) Research Hub
BioVie (BIVI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.93 USD (-2.03%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.91, market cap 0.01B. This hub links to the full technical, earnings and options research available for BIVI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.93 USD (-2.03%) |
| 52-week range | 0.82 USD – 2.48 USD |
| Trend regime | Range |
| 14-day RSI | 68.8 (Bullish) |
| Trailing P/E | -0.91 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for BIVI
Covered Call on BIVI: how it works, illustrative setup around the real 1.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BIVI: how it works, illustrative setup around the real 1.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BIVI: how it works, illustrative setup around the real 1.93 USD price, max profit/loss, breakeven and when to use it. Educational.
BIVI technical analysis: range, last 1.93 USD, RSI 68.8, 52w range 0.82 USD–2.48 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BIVI in?
BioVie (BIVI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BIVI in an uptrend or downtrend?
As of 2026-09-11, BIVI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BIVI's trailing P/E ratio?
BIVI's trailing P/E is -0.91, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does BIVI next report earnings?
BIVI is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.52 USD.